tradingkey.logo

MannKind Corp

MNKD
View Detailed Chart
5.250USD
-0.170-3.14%
Close 11/11, 16:00ETQuotes delayed by 15 min
1.61BMarket Cap
55.14P/E TTM

MannKind Corp

5.250
-0.170-3.14%
Intraday
1m
30m
1h
D
W
M
D

Today

-3.14%

5 Days

-4.20%

1 Month

+7.58%

6 Months

+15.13%

Year to Date

-18.35%

1 Year

-27.29%

View Detailed Chart

TradingKey Stock Score of MannKind Corp

Currency: USD Updated: 2025-11-11

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

MannKind Corp's Score

Industry at a Glance

Industry Ranking
81 / 407
Overall Ranking
186 / 4608
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 8 analysts
Buy
Current Rating
9.063
Target Price
+67.20%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

MannKind Corp Highlights

StrengthsRisks
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 186.16% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 53.52, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 171.20M shares, decreasing 8.44% quarter-over-quarter.
Held by Joel Greenblatt
Star Investor Joel Greenblatt holds 71.19K shares of this stock.

MannKind Corp News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

MannKind Corp Info

MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Ticker SymbolMNKD
CompanyMannKind Corp
CEODr. Michael E. Castagna, Pharm.D.
Websitehttps://mannkindcorp.com/
KeyAI